Business Context and Reporting Period
This Form 8-K is a current report filed by OncoGenex Pharmaceuticals, Inc. (Note: Metadata lists "Achieve Life Sciences, Inc." but the filing text identifies OncoGenex) on May 25, 2012. The report covers events occurring on May 25, 2012, and May 31, 2012, specifically regarding executive departures, appointments, and the results of the 2012 Annual Meeting of Stockholders.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to severance and compensation arrangements for a departing officer:
- Severance Payment (Base): CDN$30,098.59 (lump-sum) plus accrued vacation and earned wages.
- Severance Payment (Conditional on Release): CDN$88,394.23 (lump-sum).
- Benefits: Continued medical/dental coverage until August 9, 2012 (base) or February 28, 2013 (conditional).
Material Changes
Executive Departure: Cameron Lawrence, Principal Accounting Officer, Treasurer, and Senior Director of Finance, is departing effective May 31, 2012.
Executive Appointment: Michelle Burris was appointed Principal Accounting Officer and Treasurer effective May 31, 2012. She retains her existing roles as Executive Vice President, Operations, Chief Financial Officer, and Secretary.
Corporate Governance: The company held its 2012 Annual Meeting on May 31, 2012, resulting in the election of six directors and the ratification of Ernst & Young LLP as the independent auditor.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of general business risks. The primary contingency noted is the conditionality of the enhanced severance package for Mr. Lawrence, which requires him to release all claims against the company and its subsidiary.
Investor Verification Checklist
- Verify the transition of financial reporting responsibilities from Cameron Lawrence to Michelle Burris.
- Confirm the total cash outflow for Mr. Lawrence's departure (approx. CDN$118,492.82 if the release is signed).
- Review the voting results for the six elected directors to ensure board composition aligns with shareholder expectations.
- Confirm the appointment of Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2012.